Depemokimab Cuts Exacerbation Rate in Eosinophilic Asthma
By Elana Gotkine HealthDay Reporter
TUESDAY, Sept. 10, 2024 -- For patients with severe asthma with an eosinophilic phenotype, depemokimab reduces the annualized rate of exacerbations, according to a study published online Sept. 9 in the New England Journal of Medicine to coincide with the European Respiratory Society Congress, held from Sept. 7 to 11 in Vienna.
David J. Jackson, Ph.D., from King's College London, and colleagues examined the efficacy and safety of depemokimab in patients with severe asthma and an eosinophilic phenotype characterized by a high eosinophil count and a history of exacerbations despite receipt of medium- or high-dose inhaled glucocorticoids. Participants across two trials were randomly allocated to receive depemokimab (100 mg subcutaneously) or placebo at weeks 0 and 26, plus standard care (502 and 260, respectively).
The researchers found that the annualized rate of exacerbations was 0.46 and 1.11 with depemokimab and placebo, respectively, in SWIFT-1 and 0.56 and 1.08, respectively, in SWIFT-2 (rate ratios, 0.42 and 0.52). The change from baseline in the score on the St. George's Respiratory Questionnaire did not differ significantly between groups in either trial. Both groups had a similar proportion of patients with any adverse event.
"The administration of depemokimab every six months reduced the annualized rate of exacerbations among patients with severe asthma with an eosinophilic phenotype," the authors write.
Two authors disclosed ties to GSK, which funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
Severe Exacerbations Down With As-Needed Albuterol-Budesonide for Mild Asthma
FRIDAY, May 23, 2025 -- As-needed albuterol-budesonide yields a lower risk for severe asthma exacerbation among patients with mild asthma, according to a study published online...
Methotrexate Noninferior to Prednisone in Pulmonary Sarcoidosis
TUESDAY, May 20, 2025 -- For patients with pulmonary sarcoidosis, methotrexate is noninferior to prednisone with regard to the change from baseline to week 24 in the percentage of...
Use of Composite Allocation Score for Lung Transplant Wait List Improves Outcomes
MONDAY, May 19, 2025 -- Wait-list outcomes for lung transplants have substantially improved in the composite allocation score (CAS) era, according to a study presented at the...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.